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a b s t r a c t
We describe here the main natural compounds used in cancer therapy and prevention, the histor-
ical aspects of their application and pharmacognosy. Two major applications of these compounds
are described: as cancer therapeutics and as chemopreventive compounds. Both natural compounds,
extracted fromplantsor animals orproducedbymicrobes (antibiotics), and synthetic compounds, derived
from natural prototype structures, are being used. We also focus on the molecular aspects of interactions
with their recognized cellular targets, from DNA to microtubules. Some critical aspects of current cancer
chemotherapy are also discussed, focusing on genetics and genomics, and the recent revolutionary theory
of cancer: aneuploidy as the primum movens of cancer.
© 2009 Elsevier Ltd. All rights reserved.
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. Introduction
There is evidence of cancer found in ancient human remains and
n the medical literature since antiquity, dating back to the times
f the Pharaohs in ancient Egypt and the classical world. Although
t is difficult to interpret the diagnosis of physicians who lived so
any centuries ago, we can assume that many of their descriptions
elated to cases of cancer.
The ancient medical literature reports that surgery was per-
ormed but that physicians also recommended the use of some
atural, and especially plant products, which represent an interest-
ng point of comparison with current knowledge. Natural products
lay a relevant role in cancer therapy today with substantial
umbers of anticancer agents used in the clinic being either
atural or derived from natural products from various sources
uch as plants, animals and microorganisms (also of marine ori-
in) (Fig. 1). Large-scale anticancer drug discovery and screening
rograms such as those promoted by the National Cancer Insti-
ute (NCI) have played an important role in the development
f anticancer natural compounds. During the last few years,
atural-product-based drug discovery is increasing based on new
echnologies, such as combinatorial synthesis andhigh-throughput
creening, and their associated approaches. Vincristine, irinote-
an, etoposide and paclitaxel are classic examples of plant-derived
ompounds; actinomycin D, mitomycin C, bleomycin, doxorubicin
nd l-asparaginase are drugs coming from microbial sources, and
itarabine is the first drug originating from a marine source. To
ate, new generations of taxanes, anthracyclines, Vinca alkaloids,
amptothecins, as well as the novel class of epothilones have been
eveloped. Some of these are in clinical use, others in clinical trials.
ther agents originating from marine sources (both plants and ani-
als) (e.g. trabectedin—ET-743, bryostatin-1, neovastat) have also
ntered clinical trials. All these drugs are characterized by a variety
f differentmechanismsof action including for example interaction
ith microtubules, inhibition of topoisomerases I or II, alkylation
f DNA, and interference with tumour signal transduction.
This review describes the main natural compounds used in
ancer therapy and prevention. Within the framework of their his-
orical aspects and pharmacognosy, which is the study of their
atural producers, plants, animals, and microorganisms, and their
hemical composition, a variety of paradigmatic natural com-
ounds are described. These aspects are integrated and updated
y also focusing on the most recent knowledge of the molecu-
ar aspects of interactions with their recognized cellular targets,
rom DNA to microtubules. Some critical aspects of current cancer
hemotherapy are also pointed out, as well as that of a recent revo-
utionary theory of cancer: whereby not cancer gene mutations but
aretakergenesand/oraneuploidyare theprimummovensof cancer.
. History of natural cancer therapeutics
The use of botanicals – plants, herbs, fungi, seeds – as medicines
redates recordedhistoryand represents themost significantdirect
ntecedent to modern medicine. In recent times, some of the most
ncouraging clinical evidence of the value of herbs in treating can-
er permits us to reconstruct the story of these plants and their
ventual use in these cases. First of all, it is important to remember
hat themodern concept of cancer is very different from the ancient. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 376
one: the word cancer derives from the father of medicine, Hip-
pocrates, who used the Greek word Karkinos to describe tumours,
but thehistoryof cancer actuallybeginsmuchearlier. It is difficult to
identify the diagnosis of cancer in ancient texts, just from the liter-
ary description. Progress in understanding and treating cancer has
been slow and based on the development of pathological anatomy,
starting from the 18th century. The last 50 years have seen an explo-
sion in our understanding of thismost fundamental of diseases, and
new discoveries occur on an almost weekly basis. For this reason,
it is possible to find evidence of the relationship between botani-
cals and cancer only in recent times [1]. Some of themany botanical
compounds,whichhave beendemonstrated tohavepositive effects
in cancer therapy, have a long history behind them. For example, it
was recently demonstrated that the green tea antioxidant EGCG
(epigallocatechin-3-gallate) significantly slowed breast cancer
growth in female mice: its use is attested in ancient Japanese texts.
Promising and selective anti-cancer effects have been observed
withSaffron (stigmataofCrocus sativusL.) in vitroand in vivo, butnot
yet in clinical trials [2–3]. The search for anticancer lead compounds
has been themainstreamofmarine chemistry. As a result, a number
of natural marine products with unique mechanisms of action have
been identified and recently entered into clinical trials [4–5].
The use of juice, peel and oil of Punica granatum has also been
shown to possess anticancer activity, including interference with
tumour cell proliferation, cell cycle, invasion and angiogenesis [6].
Modern scientific research has revealed that the wide variety of
dietary and medicinal functions of garlic can be attributed to the
sulfur compounds present in or generated from garlic, which can
have an effective anticancer effect [7]. Myrrh is derived from the
dried resin of desert trees, Commiphora myrrha and other species.
In biblical terms, it was chosen, along with frankincense and gold,
as a gift of the Three Wise Men to the newborn Christ. Hailed for its
anti-inflammatory and disinfectant properties, myrrh has histori-
cally beenused for ailments as diverse as stomachpain, indigestion,
poor circulation, wound healing, certain skin diseases and irregular
menstrual cycles. What makes myrrh such an exciting player in the
anti-cancer field is not only how well it kills cancer cells in general,
but how it kills those that are resistant to other anti-cancer drugs. It
is believed to work by inactivating a protein called Bcl-2, a natural
factor that is overproducedby cancer cells, particularly in the breast
and prostate. Although myrrh compound does not appear to be as
powerful as other anti-cancer drugs derived from plants – such as,
vincristine, vinblastine and paclitaxel – its advantage seems to lie
in the fact that it can harm cancer cells without harming healthy
cells, something these other drugs do not do [8].
One of themost significant plant compounds in the fight against
cancer was discovered in the bark, and at low levels in the needles,
of the relatively rare Pacific Yew, Taxus brevifolia. In the 1970s, the
NCI tested plants in a number of collections, including an extract
from the Pacific Yew collected by the U.S. Department of Agricul-
ture in 1962. They discovered taxol, now named paclitaxel, which
has become one of the most effective drugs against breast and
ovarian cancer and has been approved worldwide for the clini-366 S. Nobili et al. / Pharmacological Research 59 (2009) 365–378
9. Balsamita major: a new natural candidate anticancer compound . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375cal treatment of cancer patients. Hailed as having provided one of
the most significant advances in cancer therapy, paclitaxel exerts
its anticancer activity by inhibiting mitosis. Since harvesting the
bark kills the tree and still does not provide enough paclitaxel for
the tens of thousands of cancer patients needing this treatment,
S. Nobili et al. / Pharmacological Research 59 (2009) 365–378 367
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hemists have successfully worked to synthesize the compound
rom simpler structures. In 1990, Robert A. Holton developed the
hemistry to synthesize paclitaxel from 10-deacetyl baccatin III
xtracted from the needles of the English Yew shrub which is also
ommon inEuropeand theUnitedStates, thus avoiding thedestruc-
ion of the environment through the harvest of yew trees [9]. Later
n, the same group of researchers published the first total synthesis
f paclitaxel [10]. The first clinical trials with paclitaxel were car-nd marine (C) sources of anticancer agents.
ried out in 1983 and by 1988 preliminary data showed impressive
results in patients with ovarian cancer. In the early studies involv-
ing patients with progressive disease, more than 30% experienced
tumour shrinkage and at least half of those had a response that
lasted longer than a year. This gave rise to the development of an
extensive and successful program of clinical trials in ovarian and
breast cancer. The current focus of interest afterward moved to the
development of improved analogues of this drug [11].
3 ical R
a
g
b
a
a
i
c
s
K
m
W
l
a
c
a
p
h
b
b
n
t
b
c
i
a
t
d
m
h
t
r
o
f
w
o
[
p
t
f
w
D
l
b
s
m
d
p
a
w
i
t
e
3
3
a
a68 S. Nobili et al. / Pharmacolog
The discovery of the first antibacterial agents in the 1920–1940s
lso led to an intense research for anticancer agents from microor-
anisms.
The discovery of the first anti-tumoural antibiotic was made
y Selman Waksman and H. Boyd Woodruff who in 1940 isolated
ctinomycin D from Actinomyces antibioticus [12]. This compound,
chromo-oligopeptide that acts as an inhibitor of RNA polymerase,
s a member of a group of antibiotics (actinomycins) prevalently
haracterized by antibacterial activity and all discovered by the
ame research group at Rutgers University. Farber et al. [13] and
eidan [14], described the clinical anti-tumoural activity of actino-
ycin D in a number of childhood tumours including metastatic
ilms’s tumours.
The study of anthracycline glycosides and their aglicones iso-
ated from different Streptomyces species, began in the 1950s and
chieved extremely relevant results when, in the early 1960s, a
ompound named daunomycin (also known as daunorubicin) with
ntileukaemic properties was isolated from a strain of Streptomyces
eucetius, var. caesius by Di Marco and co-workers [15]. The 14-
ydroxy derivate of daunorubicin (i.e. adriamycin), also produced
y Streptomyces peucetius and related strains, was isolated in 1969
y Arcamone et al. [16] at the Farmitalia Research Laboratories. The
ame of this compound (today known as doxorubicin) derives from
he Adriatic Sea near which the original daunorubicin strain had
een collected.
In addition to the above described terrestrial sources for anti-
ancer agents, a still almost completelyunexploredpotential source
s represented by the sea. Although oceans have attracted the
ttention of researchers since the 1950s with the discovery of
he Cryptotheca crypta sponge-derived nucleosides spongothymi-
ine and spongouridine [17], the technical difficulties of collecting
arine organisms togetherwith the poor knowledge of this habitat
ave posed a relevant obstacle. The implementation of scuba diving
ools and the development of instruments for the isolation of natu-
al products frommarine organismshave allowed the identification
f a great number of marine compounds (over 16,000) but only a
ew of these have gone though preclinical and clinical evaluation.
The history of marine anticancer agents officially starts in 1960
hen cytarabine, a pyrimidinenucleoside analogue,wasdeveloped
n the basis of the two above reported sponge-derived nucleosides
18]. This drug showed anticancer efficacy in leukaemias and lym-
homas. The use of cytarabine has nowadays been rejuvenated by
he introduction in the clinic of a liposomal formulation indicated
or the intrathecal treatment of lymphomatous meningitis.
In the same years bryostatins, a group of macrolide lactones,
ere isolated from the bryozoan species Bugula neritina. In 1970
olastatin 10 was isolated from the mollusc Dolabella auricularia
iving in the Indian Ocean; it failed to show anti-tumour efficacy
ut offered a basis for structure activity relationship studies (e.g.
ynthesis of TZT-1027, soblidotin). From then on, a variety of other
arine anticancer compounds or their semisynthetic or synthetic
erivatives have undergone the clinical investigation. Such com-
ounds include halicondrins and didemnins isolated in the 1980s
nd characterized by classical cytotoxic mechanisms of action, as
ell as compounds isolated from the end of 1990s and character-
zedbymore intriguingmechanismsof action (e.g. salinosporamide
hat inhibits proteasome or neovastat that blocks the vascular
ndothelial growth factor (VEGF) binding to its receptor) [19,20].
. Main natural cancer therapeutics.1. Tubulin-binding agents
Soluble tubulin is a heterodimer of one molecule of -tubulin
nd one molecule of -tubulin. To date, six isotypes of -tubulin
nd seven of -tubulin are known [21]. During polymerization,esearch 59 (2009) 365–378
the heterodimers link together to form protofilaments. Thirteen
of these protofilaments organized in a hollow cylinder make
up the backbone of the microtubule [22]. Microtubules are in
dynamic equilibrium with tubulin heterodimers. This equilibrium,
that is under the control of several factors, including microtubule-
associated proteins (MAPs) [23], is the target for microtubule-
disrupting agents.
Microtubules are essential components of the cell cytoskeleton
and are involved in a number of cellular functions. They are critical
to the movement of organelles during interphase and during mito-
sis, form themitotic spindle that transports daughter chromosomes
to separate poles of the dividing cell. Drugs that interfere with
microtubule function lead to failure of alignment of the daughter
chromosomes and their bipolar attachment to the mitotic spindle;
this effect leads to mitotic arrest at the metaphase/anaphase tran-
sition, followed by apoptosis [22]. This has been suggested as the
primary anti-neoplastic mechanism of action of tubulin-binding
drugs although it has also been postulated that at least part of the
anti-tumour effect of these agents is related to their effect onmicro-
tubules in interphase cells. Vinca alkaloids and taxanes represent
the main classes of tubulin-binding agents.
3.1.1. Vinca alkaloids
Vinca alkaloids are isolated from the periwinkle plant Catha-
ranthus roseus, also known as Vinca rosea. Extracts of Vinca rosea
possess many therapeutic effects including anti-tumour activity.
Vincristine, vinblastine and vindesine are the first vinca alkaloids
with anti-tumour activity to be identified. Vinorelbine is the first
new second-generation vinca alkaloid to emerge from structural
modification studies in the velbanamine or “upper” portion of the
vinblastine structure [24]. Vinflunine, a bis-fluorinated vinorel-
bine derivative, has been synthesized by superacid chemistry [24].
Due to its favourable preclinical anti-tumour activities, including
microtubule dynamics disruption, antiangiogenesis and prolonged
multidrug resistance development, vinflunine is now being widely
studied in phase I–III clinical trials [25].
The vinca alkaloids are dimeric asymmetrical compounds con-
sisting of two multi-ringed subunits, vindoline and catharantine,
linked by a carbon–carbon bridge.
Vinca alkaloids disrupt the mitotic spindle assembly through
interaction with tubulin. In particular, they bind specifically to -
tubulin and block its ability to polymerize with -tubulin into
microtubules. This leads to the killing of actively dividing cells by
inhibiting progression throughmitosis. However, newer vinca alka-
loids, such as vinorelbine and vinflunine, have proved to be weak
binders in contrast to with the strong binding of vincristine and the
intermediate level of vinblastine. Evidence indicates that vinorel-
bine and vinflunine affect microtubule dynamics differently from
vinblastine [26].
The most widely recognized mechanism of resistance to
vinca alkaloids is due to the multidrug resistance-associated P-
glycoprotein (P-gp) [27] and themultidrug resistanceprotein (MRP)
[28]. Theoverexpressionof these twoproteinsbelonging to theATP-
binding cassette (ABC) transporter family has been associated with
reduced intracellular accumulation of vinca alkaloids and corre-
sponding reduction in cytotoxicity. Bcl-XL andBcl-2 overexpression
protect vincristine and vinblastine in the absence of P-gp or other
drug resistance associated genes [29,30].
Vinca alkaloids are most commonly administered weekly by
short IV injection (1–15min), more rarely by continuous infusion.
Vinorelbine is the sole alkaloid available orally and it is adminis-
tered as a single dose weekly [31].
Classical vinca alkaloids are largely used in the treatment of
haematological and lymphatic neoplasms (especially vincristine)
as well as in several solid tumours (e.g. vinblastine in breast, tes-
ticular cancer, choriocarcinoma; vindesine in non-small cell lung
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ancer, breast cancer, etc.). The newer drugs are mostly used in
olid tumours, such as lung, breast and ovarian cancers. Side effects
ommon to these drugs are myelosuppression and neurotoxicity.
Vinorelbine is used for the treatment of non-small cell lung
ancer and metastatic breast cancer. The main toxic effect of
inorelbine is granulocytopenia with only modest thrombocy-
openia and less neurotoxicity than other vinca alkaloids [32].
influnine has been used in the treatment of bladder, non-small
ell lung and breast cancers; its main side effects are myelosup-
ression and constipation which are apparently more manageable
ompared to the other vinca alkaloids [25].
.1.2. Other microtubule destabilizing agents
The cryptophycins are a unique family of 16-membered
acrolide antimitotic agents isolated from the cyanobacteria
ostoc sp. whose molecular target is tubulin protein. They are
xtremely potent suppressors of microtubule dynamics by slow-
ng it in a concentration-dependent manner and depolymerizing
icrotubules in an irreversible way probably due to covalent
rug–target interaction. In addition, they deactivate the Bcl-2 pro-
ein and produce an apoptotic response much more quickly and
t considerably lower concentrations than clinically utilized com-
ounds. The presence of several amide and ester linkages within
he cryptophycin core provides access to very convergent total syn-
hetic approaches. However, the in vivo hydrolytic instability of the
5 ester was a key obstacle to finding a clinical candidate. This
roblemhas been somewhat ameliorated in the totally synthesized
ryptophycin-52 by increased substitution at C6 as in the presence
f gem-dimethyl substitution [33]. Despite the initial enthusiasm
eriving from the possibility that cryptophycins would be able
o overcome multidrug drug resistance in experimental systems,
his occurrence has not been confirmed in clinical trials. In addi-
ion, Cryptophycin 52 showed onlymodest activity in patientswith
latinum-resistant advanced ovarian cancer [34].
Dolastatins are peptides originally isolated from the marine
ollusc Dolabella auricularia. They inhibit microtubule assembly
nd tubulin polymerization. The pentapeptide dolastatin-10 was
he most promising natural dolastatin agent. However, while its
oxicity profile was acceptable, only minimal activity was observed
n phase II studies performed in a variety of solid tumours [35–37].
synthetic derivative of dolastatin-10, TZT-1027, seems to possess
good safety profile and some anti-tumour activity as reported in
phase I trial [38].
Halicondrins, in particular halichondrin B, were first isolated
rom the Japanese sponge Halichondria okadai. They are potent
ubulin inhibitors that non-competitively bind to the Vinca binding
ite [39]. The synthetic macrocyclic ketone derivative of halichon-
rin B, eribulin (E7389), is characterized by enhanced anti-tumour
ctivity compared to halichondrin B and is currently in phase III
reast cancer clinical trials [40].
.1.3. Taxanes
As reported in Section 2, paclitaxel, initially extracted from the
ark of Taxus brevifolia [41], is now obtained by semisynthesis
rom 10-deacetylbaccatin III, which is extracted from the needles
f the European yew tree, Taxus baccata. Docetaxel, a semisyn-
hetic taxane with anticancer activity was directly obtained from
0-deacetylbaccatin III.
With the aim of ameliorating the tolerability of taxanes and
educing clinical resistance, many efforts have been made to find
ew taxane formulations (e.g. albumin, nanoparticles, emulsions,
iposomes, polyglutamates) or new taxane analogues and prodrugs
ncluding orally bioavailable compounds [42,43].
Compounds such as abraxane, CT-2103, docosahexenoic acid
DHA)-paclitaxel, are examples of new taxanes that have shown
igher activity than paclitaxel in taxane-resistant cancers, as wellesearch 59 (2009) 365–378 369
as in tumours that have been unresponsive to paclitaxel. In addi-
tion, compared to the prototype, they have a safer toxicological
profile and their administration does not require pre-medication
for hypersensitivity reactions [44].
Paclitaxel and docetaxel are hydrophobic compounds character-
ized by a taxane ring core, estherification at the C-13 position with
a complex ester group, and an unusual fourth ring at the C-4,5 posi-
tion. The last twostructural features areessential for their biological
activity [45]. Docetaxel differs from paclitaxel in terms of only two
moiety groups [46].
Due to the poor solubility of these drugs, they are admin-
istered in formulations including two different polyoxyethylated
surfactants. Since both solvents are biologically and pharmacolog-
ically active, they lead to adverse effects such as hypersensitivity
reactions [47], peripheral neuropathies [48] or pharmacokinetic
alterations especially for paclitaxel [49].
Taxanes exhibit unique cytotoxic activity by stabilizing micro-
tubules rather than destabilizing them as vinca alkaloids do. In
particular they promote the assembly of microtubules and pre-
vent their depolymerization, thus interfering with a number of
normal cellular functions that depend on the physiological balance
between tubulin and microtubules [50,51].
Both paclitaxel and docetaxel bind to the 3-subunit of tubu-
lin, rather than to tubulin dimers, and they bind to a specific site
which is different from the binding site of guanosine triphosphate,
colchicine, vinblastine, and podophyllotoxin [52,53].
Docetaxel has a 1.9-fold higher affinity for the site than pacli-
taxel, and induces tubulin polymerization at a 2.1-fold lower critical
tubulin concentration.
Paclitaxel and docetaxel have a different effect on the cell cycle.
Paclitaxel inhibits the cell-cycle traverse at the G2-M phase junc-
tion [54] while docetaxel produces its maximum cell-killing effect
against cells in the S phase [55].
Other potential anti-tumour effects of taxanes not directly
associated with the classical anti-microtubule action have been
reported. The apoptosis induced by paclitaxel and docetaxel has
also been associated with enhanced phosphorylation of Bcl-2 [56].
In addition, paclitaxel induces the release of tumournecrosis factor-
 (TNF-) and a decrease in expression of TNF receptors [57].
The mechanisms of resistance to taxanes are not fully
understood and are likely to bemultifactorial, including the overex-
pression of the membrane efflux pump P-gp [27], the presence of
and  tubulin mutations, increased microtubule dynamics associ-
atedwith alteredmicrotubule-associatedprotein (MAP) expression
[58]. Moreover, functional aberrations in multiple molecular path-
ways, such as cell cycle control, growth promotion and apoptosis
can all contribute to taxane resistance [58].
No cross-resistance between paclitaxel and docetaxel has been
observed in several in vitro and in vivo studies in cell lines made
resistant to paclitaxel [59] and this observation has been somewhat
confirmed in clinical trials [60].
Paclitaxel and docetaxel have very high activity in a spectrum
of solid tumours (ovarian, breast, lung, head and neck, gastro-
oesophageal, bladder, testis, endometriumneoplasms) and in some
haematological and paediatricmalignancies [61,62]. Both drugs are
active as single agents and in combination chemotherapy.
The clinical success of taxanes has been accompanied by signifi-
cant side effects such as neutropenia, mucositis, hypersensitivity
reactions and neuropathy. The latter two are mainly due to the
solvents used for solubilizing these drugs and are controlled or pre-
vented by use of prophylactic medication. Peripheral neuropathy is
less frequent and less severe for docetaxel than for paclitaxel.
3.1.4. Other microtubule stabilizing agents
A series of new agents derived from different biological sources
have been identified. They include epothilones (from the soil-
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welling myxobacterium Sorangium cellulosum), discodermolide
from the Caribbean sponge Discodermia dissoluta), eleutherobin
from the soft coral Eleutherobia sp.), the sarcodictyins A-D (from
he corals Sarecodictyon roseium and Eleutherobia aurea), lauli-
alide and isolaulimalide (from the marine sponge Cacospongia
ycofijiensis).
These compounds have a common target and nearly identical
inding sites. Someof these compounds competewithpaclitaxel for
inding to microtubules and appear to bind at or near the taxane
ite (epothilones, discodermolide, eleutherobin), but others, such
s laulimalide, seem to bind to unique sites on microtubules.
All these agents possess either low level or no substrate affin-
ty for P-gp and other ABC transporters, and retain various degrees
f activity against taxane-resistant cells in vitro, but the clinical
mplications of these characteristics are not clear [44].
Among these compounds, epothilones are effective anticancer
rugs for the treatment of breast cancer patients, including those
ho have been previously treated with or are resistant to anthra-
yclines or the taxanes. Epothilone A and B are natural products
nd several of their analogues have also been investigated in clini-
al trials. Ixabepilone is the first member of the epothilone family
o be approved for clinical use. It is indicated for the treatment of
etastatic breast cancer [63,64].
Discodermolide has been the focus of intense research activity
n order to develop a practical supply route, and these efforts ulti-
ately allowed its large-scale synthesis and the initiation of clinical
rials as a novel anticancer drug [65].
.2. Topoisomerase inhibitors
The DNA topoisomerases are nuclear enzymes that reduce tor-
ional stress in supercoiled DNA, allowing selected regions of DNA
o become sufficiently untangled and relaxed to permit its replica-
ion, recombination, repair and transcription.
Inhibitors of topoisomerase I and II are anticancer drugs active
n a variety of haematological and solid tumours. They exhibit
ifferent pharmacological properties as well as different pharma-
okinetics and toxicological profiles [66,67].
The plant-derived camptothecins (irinotecan, topotecan) act
s inhibitors of topoisomerase I; the plant-derived epopodophyl-
otoxins (etoposide and teniposide) and the microbial-derived
nthracyclines (e.g. doxorubicin, epirubicin) act as inhibitors of
opoisomerase II.
.2.1. Camptothecins
In the 1950s, an extensive screening programme of the NCI
ed to the isolation of an extract of the Chinese tree Camptotheca
cuminata characterized by cytotoxic activity against a variety of
eukaemias and solid tumours. In 1966 campthotecin was identi-
ed as the active constituent of the extract [68]. Despite promising
reclinical and clinical anti-tumour activity the use of the first
amptothecin formulation was hindered by severe and unpre-
ictable toxicity. After years of intense research, in 1996 two
emisynthetic camptothecin analogues, irinotecan and topotecan,
ntered the clinics for the treatment of colorectal and ovarian can-
er, respectively [69].
Today several synthetic camptothecin analogues are in various
tages of clinical evaluation (e.g. lurtotecan, exatecan mesylate,
arenitecin, gimatecan). They present some advantages compared
o classical semisynthetic camptothecins. In particular, some of
hese are not a substrate for P-gp (gimatecan, exatecan) [66,70], and
or the breast cancer resistance protein (BCRP) (gimatecan) [70];
arenitecin is a very lipophilic compound that might show poten-
ial clinical advantages by virtue of its increased lactone stability
nd enhanced oral bioavailability [71]. These agents are currently
n phase I–II trials.esearch 59 (2009) 365–378
Camptothecin derivatives have a basic five-ring (A-E) structure
with a chiral centre located at position 20 in the terminal lactone (E)
ring [72,73]. The hydroxyl group and S-conformation of the chiral
centre to which it is attached are absolute requirements for bio-
logical activity (the hydroxyl group is essential for cytotoxicity, the
lactone ring for topoisomerase I targeting activity) [72,73].
Topotecan is a semisynthetic derivative of camptothecin with
a basic N,N-dimethylaminomethyl functional group at C-9 that
confers water solubility to the molecule. Irinotecan is a water-
soluble prodrug designed to facilitate parental administration of
the potent 7-ethyl-10-hydroxy analogue of camptothecin (SN-38).
During the catalytic cycle, topoisomerase I binds covalently to
double-stranded DNA through a reversible trans-estherification
reaction. The trans-estherification reaction leads to the formation
of covalent binding between topoisomerase I and DNA (cleavable
complex) [73]. Camptothecins causeDNAdamage by stabilizing the
covalent topoisomerase I-DNA complex, thus preventing religation
[74].
A variety of cellular mechanisms of resistance to camptothecins
which may have relevance in the clinical setting have been
described and widely reviewed [73,75]. ATP transporters such as P-
gp, MRP and especially BCRP, are responsible for the cellular efflux
of topotecan and irinotecan from tumour cells. Drug metabolism
may also play a role in the resistance of tumours to the prodrug
irinotecan, e.g. the reduced expression of the carboxylesterase-
converting enzyme that generates the active SN-38 metabolite or
the increased inactivation of SN-38 by catabolism to SN-38 glu-
curonide.
Other mechanisms of resistance may involve the target enzyme,
e.g. decreased expression or mutations of topoisomerase, post-
translational events, such as topoisomerase I phosphorylation or
poly-ADP ribosylation.
Ubiquitin/26S proteasome-dependent degradation of topoi-
somerase I may also play a role in the repair response to
topoisomerase I-mediated DNA damage. Nevertheless, it has been
shown that cells without functional p53 can undergo apoptosis
after exposure to camptothecins. Prolongation in the duration of
the cell cycle has been associatedwith resistance to camptothecins,
presumably by reducing the proportion of cells in S phase at any
given time.
Topotecan is indicated in second-line therapy against advanced
ovarian carcinoma in patients who have failed previous treatment
with platinum compounds or paclitaxel-containing chemotherapy
regimens [76]. The dose-limiting toxicity for topotecan is neutrope-
nia, with or without thrombocytopenia [77]. The major therapeutic
indication for irinotecan is thefirst-line treatmentofmetastatic col-
orectal cancer patients in combination with 5-FU [78], and recently
also with the monoclonal antibody bevacizumab [79]. Encouraging
results have also been reported in other types of solid tumours (e.g.
small cell and non-small cell lung cancer, cervical, ovarian cancers).
The dose-limiting toxicities are delayed diarrhoea and neutropenia
[66]. A cholinergic syndrome resulting from inhibition of acetyl-
cholinesterase activity by irinotecan also frequently occurs within
the first 24h after dosing [80].
3.2.2. Epipodophyllotoxins
Podophyllotoxins have a long therapeutic history. Extracted
from the root of the Indian podophyllum plant (Podophyllum pelta-
tum), podophyllotoxin was used as a remedy by the American
Indians for its emetic, cathartic, and anthelminthic effects. From
a wide program of chemical synthesis (about 600 derivatives from
1950s to 1960s), two active compounds, etoposide and teniposide,
emerged. Unlike other podophyllotoxin derivatives, etoposide and
teniposide have no effect on microtubular structure or function at
concentrations used in the clinic [81].
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Etoposide and teniposide are similar in their action and in their
pectrum of human tumour activity. DNA topoisomerase II is the
ey cellular target for both etoposide and teniposide. Topoiso-
erase II is a nuclear enzyme which alters DNA tertiary structure
y creating transient double-stranded breakage of the DNA back-
one, thus allowing subsequent passage of a second intact DNA
uplex through the break [82]. Etoposide and teniposide form
ternary complex with topoisomerase II and DNA and prevent
esealing of the DNA break. During the presence of epipodophyllo-
oxins, the topoisomerase II-DNA intermediate cannot be reversed,
esulting in DNA double strand-breaks leading to cell death. Both
pipodophyllotoxins are substrates for membrane efflux pumps,
ncluding P-gp. Amplification of the mdr-1 gene that encodes P-
p,hasbeenobserved inepipodophyllotoxin-resistant cells. Clinical
tudies combining etoposidewithnon-cytotoxic substrates for P-gp
e.g. PSC 833) have been performed in attempts to circumvent this
echanism of drug resistance. Othermechanisms of resistance due
omutations or decreased expression of topoisomerase II have been
escribed in epipodophyllotoxin-resistant cells [81]. Mutations of
53 have also been found to represent a mechanism of resistance
n cell lines resistant to epipodophyllotoxins [83].
The approved indications for etoposide are lung cancer, chori-
carcinoma, ovarian and testicular cancers, lymphoma and acute
yeloid leukaemia.
Teniposide is approved for central nervous system tumours,
alignant lymphoma, and bladder cancer [66].
Myelosuppression is a common adverse effect of etoposide;
eucopoenia is the dose-limiting toxicity while thrombocytopenia
ccurs less often and usually is not severe. Gastrointestinal toxici-
ies (nausea, vomiting, stomatitis, mucositis) occur in about 15% of
atients treated with IV etoposide and in about 55% treated with
ral etoposide. Alopecia is common but reversible. Hypersensitiv-
ty reactions to both drugs have been observed [84,85]. However,
hese adverse effects are primarily due to the adjuvants used in the
arenteral formulations, rather than to the drugs [66].
.2.3. Anthracyclines
After daunorubicin and doxorubicin, a series of semisynthetic
ompounds (e.g. idarubicin, epirubicin) followed and entered
linical use. Today a series of new anthracycline formulations
ave been approved for use in the clinic (e.g. liposomal for-
ulations) and new analogues fully synthesized anthracycline
re in the advanced phases of clinical studies (e.g. sabarubicin,
EN 10755, nemorubicin). All anthracyclines share a quinone-
ontaining rigid planar aromatic ring structure (the chromophore)
ound by an O-glycosidic bond to an aminosugar [86]. Several
undred structural analogues have been obtained by synthetic
odification of daunorubicin or doxorubicin. The commonquinone
oiety in the anthracycline ring structure can readily partici-
ate in oxidation–reduction reactions that ultimately generate
ighly reactive chemical species thought to be responsible for
nthracycline-induced cardiotoxicity. Thus small modifications,
uch as the different orientation of the C-4 hydroxyl group on the
ugar in epirubicin compared to doxorubicin are able to reduce
ardiotoxicity, preserving the anticancer activity [67].
Anthracyclines induce inhibition of topoisomerase II religation
eaction, causingaccumulationofprotein-linkeddoubleandsingle-
trand DNA breaks (cleavable complex), which ultimately lead to
ytotoxic DNA damage and cell death [87,88]. However, the pre-
ise steps by which anthracyclines stabilize DNA topoisomerase
I cleavage complex are not fully understood and may in fact be
ndependent of DNA intercalation [89]. Anthracyclines are able to
enerate oxygen free radicals by at least two distinct pathways [90],
ut it is not clear if this contributes to cell death and antiprolifera-
ive effects. All anthracyclines are substrates for the P-gp-mediated
rug effluxpumpand theoverexpressionof P-gp represents amajoresearch 59 (2009) 365–378 371
mechanism of cellular resistance to these drugs [27]. Also MRP
causes resistance to anthracyclines [91].
Drug resistance may also be due to gene mutations or down-
regulation of topoisomerase II [92]. Doxorubicin exhibits a broad
spectrum of activity and remains one of the most effective anti-
cancer drugs. It iswidely used in the treatment of breast carcinoma,
small cell lung cancer, ovarian carcinoma and lymphomas. Epiru-
bicin has the same profile, but it is generally used in adult solid
tumours rather than in other malignancies. Daunorubicin and
idarubicin are mainly used for the treatment of adult and paedi-
atric leukaemias, although they show activity also in lymphomas or
breast cancer [86]. The side effects of doxorubicin anddaunorubicin
include bonemarrowdepression, stomatitis, alopecia and gastroin-
testinal and dermatological toxicity. Cardiac toxicity is a peculiar
adverse effect observed with these agents. It is characterized by
myocardial dysfunction and congestive heart failure. Epirubicin
and idarubicin, that have been developed to improve therapeutic
and pharmacological properties of the natural compounds, show
reduced cardiotoxic effects.
4. Other natural anticancer compounds
4.1. From plant sources
Other examples of plant-derived compounds currently under
investigation are flavopiridol, homoharringtonine, -lapachone,
combretastatin A4. Flavopiridol is a synthetic flavone derived from
the plant alkaloid rohitukine, which was isolated from the leaves
and stems of Amoora rohituka and later from Dysoxylum binectar-
iferum [93]. Flavopiridol is a cyclin-dependent kinase inhibitor [94].
The agent is currently in phase I–II clinical trials [95,96]. Avail-
able evidence indicates encouraging response rates in a variety of
solid and haematological malignancies and diarrhoea as the dose-
limiting toxicity. Based on in vitro synergy of flavopiridol with
several conventional cytotoxic agents, combination clinical studies
toevaluateflavopiridolwithpaclitaxelor cisplatinagainst advanced
solid tumours are ongoing.
Homoharringtonine is an alkaloid isolated from the Chinese tree
Cephalotaxusharringtonia [97]; it is characterizedbyefficacyagainst
various leukaemias [98] and currently in phase II–III. The princi-
pal mechanism of action of homoharringtonine is the inhibition of
protein synthesis, blocking cell-cycle progression [99].
-lapachone is a quinone obtained from the bark of the lapacho
tree (Tabebuia avellanedae). It is a DNA topoisomerase I inhibitor
that induces cell-cycle delay at G1 or S (synthesis) phase before
inducing either apoptotic or necrotic cell death in a variety of
human carcinoma cells, including ovary, colon, lung, prostate and
breast [100]. It is currently investigated in a phase I–II study [40].
Combretastatin A4, isolated from the stem wood of the South
Africa tree Combretum caffreum, is a vascular disruptive agent. It
inhibits tumour blood vessel growth, causing tumour cell death
and necrosis. Phase I trials have shown some clinical activity of
combretastatin A4 and a favourable toxicological profile [101].
4.2. From microbial sources
New compounds derived from microorganisms include
rapamycin and geldanamycin. Rapamycin (sirolimus) is amacrolide
compound obtained from Streptomyces hygroscopicus. Rapamycin
is a potent immunosuppressant and also possesses antifungal and
antineoplastic properties. Rapamycin acts as a specific inhibitor
of m-TOR (mammalian target of rapamycin) that is a downstream
mediator of PI3K/Akt [102]. Thus it selectively blocks transcrip-
tional activation, leading to tumour cell growth and division.
Geldanamycin, an analogue of rapamycin, is a benzoquinone
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nsamycin natural fermentation product from the same microbial
ource that binds to, and inhibits the 90kDa heat-shock protein
SP 90 [103]. In this way, it is also able to suppress the protein
inase activity of m-TOR [104]. Both agents are currently in phase
–II studies [40].
The tumour-inhibitory properties of the bacterial enzyme l-
sparaginase were discovered more than 50 years ago [105,106]
nd since then, l-asparaginases, have been used in the treatment
f a variety of lymphoproliferative disorders and lymphomas, in
articular acute lymphoblastic leukaemia, in combination with
ther anticancer agents, in children and in adults. The mecha-
ism of action of l-asparaginase is represented by the depletion of
sparagine, an amino acid essential to leukaemia cells, and by the
ubsequent inhibition of protein synthesis leading to cytotoxicity.
lthough l-asparaginase has been found in various plant and ani-
al species,microorganisms are themost efficient and inexpensive
ources of this enzyme. A variety of microbes including bacteria,
ungi, yeast, actinomycetes and algae, produce l-asparaginase but
hat used in the clinic is from two bacterial species, viz. Escherichia
oli and Erwinia caratovora. The efficacy of this drug is limited by
he occurrence of hypersensitivity reactions and development of
nti-asparaginase antibodies. In order to decrease the immuno-
enicity of the enzyme and to prolong its half-life, a form of E. coli
-asparaginase covalently linked to polyethylene glycol has been
ynthesized [107]. The pegylated form of asparaginase has been
pproved by the Food andDrugAdministration (FDA). On July 2008,
he European Medicines Agency (EMEA) recognized for pegylated
-asparaginase the status of “orphan drug” and its use for the treat-
ent of acute lymphoblastic leukaemia.
.3. From marine sources
Marine compounds that have reached clinical investigation are
rabectedin (or ET-743) isolated from Ecteinascidia turbinata, bryo-
tatin, a macrolide lactone isolated from a species of bryozoan,
ugula neritina, kahalalide F, a cyclodepsipeptide toxin isolated
rom the mollusc Elysia rubefescens, didemnin B isolated from
arribean tunicate, and the second generation didemnin aplidine
solated from Aplidium albicans. More recently also other com-
ounds such as squalamine, isolated from the dogfish shark Squalus
canthias, LAF389, a synthetic analogue of bengamide B (a com-
ound isolated fromthe Jaspis spongesof the coral reefs near the Fiji
slands and Australia), and neovastat, a derivative of shark cartilage
xtract have been developed to the stage of clinical trials.
Most of these compounds have been recognized by the FDA and
heEMEAas “orphandrugs” for the treatmentof variousneoplasms.
Among the previously mentioned compounds, trabectedin has
eceived themost extensive clinical investigation. It has shownclin-
cal activity in a broad spectrum of solid tumours and in September
007, EMEA granted its marketing authorization for the treatment
f soft tissue sarcoma after failure of standard chemotherapy [108].
n addition positive results from a randomized phase III study
omparing trabectedin with pegylated liposomal doxorubicin vs
egylated liposomal doxorubicin alone in ovarian cancer patients
ave been recently published [109].
These agents are characterized by different pharmacological
roperties. Although the exact mechanism of action of trabectedin
s still not clearly defined, it is substantially a DNA and transcription
nteracting agent. This complex mechanism of action is due to the
rug chemical structure comprised of three fused tetrahydroiso-
uinoline rings. Two of them bind covalently to the minor groove
f DNA and the third protrudes out of the minor groove and may
irectly interact with transcription factors (e.g. SP-1) [110]. Various
nd conflicting reports about whether trabectedin is a substrate
or P-gp have been published [27]. Bryostatin acts as a modula-
or of protein kinase C (PKC) activity, and enhances the effect ofesearch 59 (2009) 365–378
chemotherapeutic agents such as paclitaxel an inhibitor of PKC
[111].
The mechanism of action of kahalalide F is not yet well eluci-
dated;however, preliminaryevidence suggests specific interactions
withmembranes or proteins. The agent is under evaluation inphase
I–II studies for the treatment of solid tumours. The mechanism
of action of didemnin B and aplidine involves several pathways,
including cell cycle arrest, inhibition of protein synthesis and
antiangiogenic activity. Aplidine is characterized by delayed neu-
romuscular toxicity that requires careful follow-up but displays
promising anti-tumour activity. It is currently in phase I–II trials
[20].
Compounds such as squalamine, LAF389 and neovastat have
shown antiangiogenic activity. Targets of squalamine and LAF389
are the phospholipid bilayer by inhibition of the sodium-
hydrogen antiporter sodium-proton exchangers and the methio-
nine aminopeptidase, respectively. Neovastat inhibits the binding
of VEGF to its receptor [19,20].
LAF389 has been studied in a phase I trial [112]. Squalamine
and neovastat are currently evaluated in phase II and III studies,
respectively [40].
5. Chemopreventive compounds from natural sources
Chemoprevention is a promising anticancer approach aimed at
reducing the morbidity and mortality of cancer by delaying the
process of carcinogenesis. Curcumin is one of the most studied
chemopreventive agents. It is a natural compound extracted from
the rhizome of Curcuma longa L. that allows suppression, retarda-
tion or inversion of carcinogenesis. Curcumin has also been shown
to possess anti-tumour activity in a variety of in vitro tumour mod-
els (cell lines from solid tumours and leukaemia) as well as in
tumour animal models. Its particular toxicological profile (doses
up to 8000mg/day are still safe) has allowed the development of
a large number of phase II studies [113,114]. As chemopreventive
agent, curcumin is currently in phase II studies in colorectal cancer
patients [114].
Another candidate chemopreventive agent is resveratrol, a
polyphenol found in numerous plant species, includingmulberries,
peanuts and grapes. Its potential chemopreventive and chemother-
apeutic activities have been demonstrated in all three stages of
carcinogenesis (initiation, promotion, and progression), in both
chemically andUVB-induced skin carcinogenesis inmice, aswell as
in variousmurinemodels of human cancers. Evidence fromnumer-
ous in vitroand in vivo studieshave confirmed its ability tomodulate
various targets and signalling pathways [115]. As a chemopreven-
tive agent, resveratrol is currently in phase I studies in colorectal
cancer patients and in healthy subjects at high risk of developing
melanoma [40].
6. Nutraceuticals and functional foods
6.1. Nutraceuticals
A nutraceutical is a product isolated or purified from foods that
are generally sold in a medicinal form not usually associated with
foods. The term initially arose by combining “nutrition” and “phar-
maceutical”, and was defined as a food that provided medical or
health benefits. Nutraceutical has to be demonstrated to possess
protective action against chronic diseases or to have physiologi-
cal benefit. The concept generally refers to dietary supplements
that contain a concentrated form of bioactive substance originally
derived from food [116].
The examples of nutraceuticals with claimed benefits include
resveratrol from red grape products as an antioxidant, soluble
ical Research 59 (2009) 365–378 373
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Table 1
Potential benefitsof foodsupplementationwith functional components fromnatural
sources.
Functional components Source Potential benefits
Lycopene Tomato products Reduces the risk of prostate
cancer
Insoluble fibre Wheat bran Reduces the risk of breast
or colon cancer
Beta-glucan Oats, barley Protects against heart
disease and some cancers
Soluble fibre Psyllium Protects against heart
disease and some cancers
Conjugated linoleic acid
(CLA)
Cheese, meat
products
Improves body
composition, decreases risk
of certain cancers
Anthocyanidins Fruits Neutralize free radicals,
reduce risk of cancer
Catechins Tea Neutralize free radicals,
reduce risk of cancer
Flavonones Citrus Neutralize free radicals,
reduce risk of cancer
Flavones Fruit/vegetables Neutralize free radicals,
reduce risk of cancer
Lignans Flax, rye, vegetables Prevention of cancer, renalS. Nobili et al. / Pharmacolog
ietary fibre products such as psyllium seed husk for reducing
ypercholesterolemia, sulforaphane from broccoli as a cancer pre-
entive and isoflavonoids from soy or clover which improve arterial
ealth. However, only the beneficial effect of psyllium as a fibre
roduct has been sufficiently documented in human clinical tri-
ls to receive approval by the FDA for the health claim statements
n its product labels.
Other nutraceuticals include flavonoid antioxidants, such as
lpha-linolenic acid from flax seeds, beta-carotene from marigold
etals, anthocyanins from berries. Several other compounds have
een added to the list of dietary supplements mentioned by the
DA and many botanical and herbal extracts such as ginseng, garlic
il etc. have been developed.
Clinical therapeutic effects of nutraceuticals have been studied
n large epidemiological studies and trials on the use of varying
utritional supplements to prevent cancer. The European Prospec-
ive Investigation into Cancer and Nutrition trial (EPIC) began in
992 and is focused on identification of dietary determinants of
ancer. This study has involved more the 520,000 participants in
0 countries and the preliminary data demonstrated a reduction in
olorectal cancer with increased fibre intake [117].
Other nutraceuticals have been proposed as chemopreventive
gents for colorectal cancer. Yellow mustard oil, which belongs to
he Brassica family, has been reported to possess anticancer prop-
rties. The recent research by Prof Eskin’s group at the University
f Manitoba, Canada, demonstrated that mustard gum containing
complex mixture of extractable polysaccharides exerted a pro-
ective role in the development of colon cancer in preclinical rat
odels [118].
Bioactive plant compounds can interact with host cells, sub-
equently altering intracellular signal transduction pathways
nvolving the transcription factors NF-kB, AP1 [119], and NF-E2-
elated factor 2 (Nrf2) [120]. In particular, a dual role of Nrf2,
ither in chemoprevention or chemoresistance, has been recently
ecognized [120]. Chemopreventive compounds (e.g. sulforaphane,
urcumin, resveratrol) are able to transcriptionally activate theNrf2
arget genes to trigger a cytoprotective response [121]. However,
rf2 protects not only normal cells from transforming into cancer
ells, but also promotes the survival of cancer cells in detrimental
nvironments. Genetic alterations of the Nrf2 inhibitor Kelch-like
CH-associated protein (Keap1) impair its ability to repress Nrf2 in
ancer. The consequent increased transcriptionofNrf2downstream
enes leads to increased expression of proteins (e.g. antioxidant
nd detoxicant enzymes, gene encoding transporters) that confers
growth advantage and drug resistance to cancer cells. [122]. These
ndings pose a relevant question on the use of Nrf2 activators as
hemopreventive agents in patients where early steps of cancero-
enesis might have been initiated as well as on the effects of their
atient self-use in association to cancer chemotherapy.
.2. Functional foods
A functional food is, or may be, similar in appearance to a con-
entional food that is consumed as part of a normal diet, but
emonstrates physiological benefits and/or reduces the risk of
hronic disease beyond basic nutritional functions and contains
ioactive compounds. Some examples of functional food compo-
ents obtained from the International Food Information Council
re presented in Table 1.
Increasing numbers of people use dietary vegetables, medici-
al herbs and plant extracts to prevent or treat cancer. The Indian
ystem of medicine, named Ayurveda, leads the way in the use
f natural compounds. Many plant products are in use as herbal
edicinals, as food supplement or as spices in daily cooking. Some
f them have been studied in various in vivo and in vitro exper-
mental models of cancer, and have been shown to significantlyfailure
Isoflavones: daidzein and
ganistein
Soybeans and
soy-based foods
Protect against some
cancer and heart disease
inhibit cancer cell proliferation [123,124]. An example of Ayurvedic
supplement food is the Maharishi Amrit Kalash (MAK), an herbal
formulation composed of two herbal mixtures, MAK-4 and MAK-5
with claimed potential to significantly inhibit the in vitro growth
of cancer cells from human tumours [125]. Although these com-
pounds were also able to inhibit the tumour progression in animal
models [126], no reports of trials on these two herbal remedies
in cancer patients are available at present. Many other herbs and
spices such as turmeric (curcumin) and garlic are however being
tested in clinical trials [40].
7. Molecular mechanisms of natural anticancer compound
activity: gene specific and aspecific targeting
Throughout history, natural products have been a rich source
of compounds that have found many applications in the fields of
medicine, pharmacy and biology. In the cancer field, a number of
importantnewcommercializeddrugshavebeenobtained fromnat-
ural sources, by structural modification of natural compounds, or
by the synthesis of new compounds, designed following a natu-
ral compound as model. The search for improved cytotoxic agents
continues to be important in the discovery of modern anticancer
drugs. The huge structural diversity of natural compounds and their
bioactivitypotential havemeant that several products isolated from
plants, marine flora and fauna, microorganisms can serve as lead
compounds whereby their therapeutic potential is improved by
molecular modification.
Additionally, semisynthetic processes of new compounds,
obtained bymolecularmodification of the functional groups of lead
compounds, are able to generate structural analogues with higher
pharmacological activity and with fewer side effects. These pro-
cesses, complemented with high-throughput screening protocols,
combinatorial chemistry, computational chemistry and bioinfor-
matics can provide compounds that are far more efficient than
thosecurrentlyused inclinical practice. Combinatorial biosynthesis
is also applied for the modification of natural microbial products.
Likewise, advances in genomics and the advent of biotechnology
have improved both the discovery and production of new natural
compounds.
DNA damage can induce apoptosis. Apoptosis is also widely
believed to be the major anti-proliferative mechanism of DNA-
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amaging anticancer drugs. However, induction of apoptosis of
arcinoma cells generally requires drug concentrations that are at
east one order of magnitude higher than those required for loss
f clonogenicity. This is true for different DNA-damaging drugs
uch as cisplatin, doxorubicin and camptothecin. Here, we discuss
poptosis induction by DNA-damaging agents using cisplatin as an
xample. Recent studies have shown that cisplatin induces caspase
ctivation in enucleated cells (cytoplasts lacking a cell nucleus).
isplatin-induced apoptosis in both cells and cytoplasts is associ-
ted with rapid induction of cellular reactive oxygen species and
ncreases in Ca2+. Cisplatin has also been reported to induce clus-
ering of Fas/CD95 in the plasma membrane. Available data suggest
hat the primary responses to cisplatin-induced DNA damage are
nductionof long-termgrowth arrest (“premature cell senescence”)
nd mitotic catastrophe, whereas acute apoptosis may be due to
off-target effects” not necessarily involving DNA damage.
. Aneuploidy of cancer, a new possible target for natural
ompounds
More then 200 years ago, the researchers studying micro-
copic images of human tumour cells noticed that these cells often
ontained excessive numbers of chromosomes. Instead, the nor-
al cells found in surrounding stroma contained an invariable
omplement of 46 chromosomes. Subsequently, it was demon-
trated that human cancer cells could possess between 60 and
0 chromosomes and that they differed from each other by the
umber of chromosomes they contained. Moreover, these chromo-
omes demonstrated structural aberrations: inversions, deletions,
uplications and translocations. These numerical and structural
bnormalities were defined as aneuploidy. Today, even after more
han two centuries of cancer research worldwide it is still unclear
f the somatic mutation that causes cancer is the one that alters the
umber of chromosomes (causes aneuploidy), or one that alters
pecific genes. Most cancer phenotypes are unstable and this phe-
omenon became known as the “genetic instability” of cancer
ells. Duesberg and others [127], based on its mutagenic potential,
ave recently reconsidered aneuploidy as a cause of cancer. These
esearchershypothesized that aneuploidyalters thedosageof thou-
ands of structural and regulatory gene products as a result of
Fig. 2. Images of Balsamite major Desf. were obtained from the archives of Oesearch 59 (2009) 365–378
multiplication or division of complete biochemical pathways, and,
by doing so, offers a plausible explanation for the many dominant
phenotypes of cancer genes. This hypothesis would exactly explain
the cancer-specific DNA indices, expression profiles of thousands
of genes, neoantigens, autonomous growth, nuclear morphology
alterations usually not observed in conventional gene mutations.
Themechanismof carcinogenesis via aneuploidy is divided into two
stages; thefirst stage requires generationof aneuploidybyexposure
to genotoxic physical carcinogens (X-rays, radiation) fragmenting
chromosomes or by mutation of genes regulating mitosis. There
is much evidence that cancers being caused by genotoxic physical
and chemical carcinogens are always aneuploid. The second stage
requires generation of neoplastic karyotypes via autocatalytic kary-
otype variation and evolution resulting from imposed imbalance
on the genes of the spindle apparatus, causing abnormal ratios of
spindle proteins, centrosomal proteins and even abnormal num-
bers of centromers. According to Duesberg’s theory, the process
of aneuploidy-catalyzed chromosome re-assortment would gen-
erate lethal, pre-neoplastic and neoplastic karyotypes and would
require a very long time from exposure to the carcinogen to com-
mencement of carcinogenesis. By contrast, themutationhypothesis
predicts instant neoplastic transformation as observed exclusively
in the case of oncogenic retroviruses.
The aneuploidy theory of cancer, although controversial at
present, could have a practical value for cancer patients. Accord-
ing to David Rasnick, aneuploid tumour stability could be easily
disrupted by environmental changes such as major changes in diet
[128]. The slow acceptance of this theory has already stimulated
research into compounds that cause or prevent aneuploidy.
Numerous epidemiological studies have demonstrated a lower
risk of cancer among individuals whose diet includes a rela-
tively large amount of vegetables, fruits and plant products, all
containing different vitamins and micronutrients with ability to
prevent carcinogenesis by interfering with detrimental actions
of mutagens, carcinogens and tumour promoters. Recent studies
demonstrate that plants rich in compounds such as avicins (triter-
penoid saponins) are able to inhibit oxidative stress and promote
apoptosis of pre-malignant andmalignant cells of skin cancer in the
murine model, suggesting the potential to prevent other epithelial
tumours also in humans [129].
fficina Profumo-Farmaceutica “Santa Maria Novella” Florence, Italy.
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. Balsamita major: a new natural candidate anticancer
ompound
Recently, the preliminary assessment of the anti-inflammatory
ntioxidative and possible anti-tumour properties of Balsamita
ajor Desf. commonly known as a costmary (Fig. 2), has been
ompleted at the Consiglio Nazionale delle Ricerche (CNR) Istituto
er lo Studio degli Ecosistemi of Florence in collaboration with the
niversities of Siena and Pisa (Italy) and the Officina Profumo Far-
aceutica Santa Maria Novella, a historical “institution” of herbal
edicine and cosmetics established in 1612 and continually oper-
ting in Florence, Italy. The preliminary data demonstrate a rich
ource of potential natural antioxidants and anti-inflammatory
ompounds present at relatively high concentration in aqueous
xtracts of the dry plant, without any cytotoxic effects detected so
ar. The anti-inflammatory effect was demonstrated to be medi-
ted via inhibition of IL-6 expression by human peripheral blood
ononuclear cells (monocytes stimulated by bacterial lipopolysac-
haride) and confirms the historical importance of Balsamite major
esf in herbal medicine.
0. Conjugation of psolaren with antisense
ligonucleotides: a chimera of old and new
The antisense strategy is widely used to modulate gene expres-
ion at a post-transcriptional level both as a research tool and as
otential cancer gene therapy [130].
A vexata quaestio is how antisense oligonucleotides are actually
ancer gene specific, which requires that its target be restricted to
ancer cells and be absent in their normal counterpart. Chromo-
omal translocations or inversions are the only targets responding
o this requirement. Indeed, cancer specificity of a variety of anti-
ense oligonucleotides targeting either hybrid transcripts or hybrid
enes has been proven [131,132]. However, because of the high
enetic variability of cancer cells, any one-gene targeting antisense
ligonucleotide cannot succeed in killing cancer. Thus, potential
ntisense therapeutics are now exploited in combination with
onventional anticancer drugs (including natural compounds) tar-
eting signalling pathways of proliferation and apoptosis [133].
Psoralen is a natural photodynamic compound belonging to
he family of furocoumarins, whose chemical structure consists
f a furan ring fused with coumarin. It is produced by a variety
f plants as a natural defence against pest. It occurs in Psoralea
orylifolia, from which the natural compound derives its name, as
ell as in the common fig, celery, parsley, and parsnips. Given its
xtended -electron system, psoralen displays UV light-induced
hotosensitizing activity, useful in photodynamic treatment of var-
ous diseases, including psoriasis, vitiligo and other skin conditions
ike cutaneous T-cell lymphoma [134,135]. Psoralene forms inter-
trand cross-links as well as thymine monoadducts with DNA upon
V light activation. Photodynamic treatments consist of the topical
r oral application of psoralen followed by exposure to photoacti-
ating UV light in the range of 315–400nm of wavelength (PUVA).
Conjugation of established anticancer drugs to cancer specific
ntisense oligonucleotides to give rise to new highly synergistic
himeric therapeutics has been proposed. As a paradigm, conju-
ates of psoralen or its derivatives with antisense oligonucleotides
argeting cancer specific fused genes derived fromgenomic translo-
ations have been synthesized. The potent, generalized, cytotoxic
ffects of psoralen are timely and spatially restricted by cooper-
tion of the antisense moiety of the chimera, which specifically
argets the fusion gene. Thus, they are exerted based on the ability
f psolaren to be activated by UV light, only on the condition that
ntisense complements its target.
Psoralen-conjugated antisense oligonucleotides have been suc-
essfully used to silence specific genes involved in cancerogenesis,esearch 59 (2009) 365–378 375
such as mutated K-Ras mRNA [136], human papillomavirus E6
oncogene protein mRNA [137] and c-myc mRNA [138].
11. Conclusions
The medical treatment of cancer has made substantial improve-
ments since the early years of modern anti-tumour drug research.
A selected number of human malignancies (e.g. childhood lym-
phoblastic leukaemia, lymphomas and testicular cancer) can be
cured with the today’s therapies and prolonged survival has been
obtained in several others [139]. The identification and develop-
ment of natural compounds and their derivatives have greatly
contributed to this progress andmany of these compounds are now
being used in clinical practice.
Nature is still today a rich source of active principles against
cancer cells. Natural compounds comprise either classical cyto-
toxic moieties targeting nonspecific macromolecules expressed
by cancer cells and to a lesser extent by normal proliferating
cells (e.g. DNA, enzymes, microtubules) or new compounds tar-
geting macromolecules specifically expressed on cancer cells (e.g.
oncogenic signal transduction pathways). Another relevant field
of application of natural compounds is cancer chemoprevention
since these compounds may inhibit specific processes involved in
cancerogenesis. Even the popular press frequently publishes arti-
cles about cancer chemoprevention and its potential benefits and
always reports about newly discovered exotic natural compounds
with possibly relevant preventive properties. However, despite a
robust molecular rationale for this strategy, preclinical and clin-
ical data in this field are still scanty and no controlled clinical
trial has yet been published demonstrating relevant clinical advan-
tages.
It is important to emphasize that only rigorous preclinical and
clinical studies along with a precise understanding of the phar-
macology of new compounds may assure the selection of active
and safe anticancer and chemopreventive drugs, including natural
compounds.
A controversial issue relates to the spontaneous use by can-
cer patients of complementary therapies comprising nutraceuticals
and functional food. Few diseases evoke as much emotion, psy-
chological and physical pain as cancer. This justifies the desperate
search by cancer patients for therapies that hold the promise of a
concrete breakthrough and cure beyond the remedies that physi-
cians can offer them. The attention of the media on these topics
is high and stimulates the expectations of patients, relatives and
the entire society, sometimes even unduly, by inducing glimmers of
hopewhichmay be unrealistic. Extreme cautionmust be exerted in
allowing patients to assume complementary therapies since today
no data on their therapeutic benefits are available and they may
induce relevant side effects and drug interactions. The use of com-
plementary therapies in addition to the standard chemotherapy
may also produce detrimental effects as recently suggested for vita-
min C in in vitro models [140], despite other promising preliminary
preclinical and clinical data [141].
In conclusion, the application of natural compounds in the treat-
ment of cancer, the very common “plague” of our modern times,
has resulted in increased therapeutic efficacy. Research results both
testify to the evolution of knowledge coming from pharmacognosy
and its historical roots in ancient herbal medicine, as well as to the
great possibilities of future progress by means of a rational, natural
product-based drug discovery approach.Acknowledgements
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